Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 14;181(5):967–975. doi: 10.1111/bjd.17919

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR) for patients receiving continuous adalimumab (ADA) every week (ADAew) across PIONEER I, II and open‐label extension (OLE). Patients in this analysis are those who received ADAew in both study periods (all‐ADAew population, N = 99). This analysis includes data from both study periods, in addition to the OLE data for the all‐ADAew population who discontinued Period B owing to loss of response, entered the OLE, and regained response in the OLE. This demonstrates maintenance of treatment response for patients who may regain response following temporary loss of response.